

**BAXTER INTERNATIONAL INC.**  
**Key Product Line Sales by U.S. and International**  
**Three-Month Periods Ending December 31, 2011 and 2010**  
**(unaudited)**  
**(\$ in millions)**

	Q4 2011			Q4 2010			% Growth		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
<b>BioScience</b>									
Recombinants	\$246	\$332	\$578	\$230	\$304	\$534	7%	9%	8%
Plasma Proteins	106	291	397	126	290	416	(16%)	0%	(4%)
Antibody Therapy	290	116	406	257	129	386	13%	(10%)	5%
Regenerative Medicine	81	69	150	83	62	145	(2%)	11%	3%
Other <sup>1</sup>	12	32	44	7	45	52	67%	(29%)	(16%)
<b>Total BioScience</b>	<b>\$735</b>	<b>\$840</b>	<b>\$1,575</b>	<b>\$703</b>	<b>\$830</b>	<b>\$1,533</b>	<b>5%</b>	<b>1%</b>	<b>3%</b>
<b>Medical Products<sup>2</sup></b>									
Renal	\$96	\$568	\$664	\$101	\$525	\$626	(5%)	8%	6%
Global Injectables <sup>3</sup>	232	255	487	264	235	499	(12%)	9%	(2%)
IV Therapies	166	303	469	145	307	452	14%	(1%)	4%
Infusion Systems	137	98	235	132	98	230	4%	0%	2%
Anesthesia	92	55	147	87	54	141	6%	2%	4%
Other	3	8	11	2	6	8	47%	29%	33%
<b>Total Medical Products<sup>3</sup></b>	<b>\$726</b>	<b>\$1,287</b>	<b>\$2,013</b>	<b>\$731</b>	<b>\$1,225</b>	<b>\$1,956</b>	<b>(1%)</b>	<b>5%</b>	<b>3%</b>
<b>Transfusion Therapies<sup>4</sup></b>	<b>\$5</b>	<b>\$1</b>	<b>\$6</b>	<b>\$6</b>	<b>\$3</b>	<b>\$9</b>	<b>(17%)</b>	<b>(67%)</b>	<b>(33%)</b>
<b>Total Baxter<sup>3</sup></b>	<b>\$1,466</b>	<b>\$2,128</b>	<b>\$3,594</b>	<b>\$1,440</b>	<b>\$2,058</b>	<b>\$3,498</b>	<b>2%</b>	<b>3%</b>	<b>3%</b>

<sup>1</sup> Principally includes vaccines and sales of plasma to third parties.

<sup>2</sup> Medical Products represents the combination of the company's former Medication Delivery and Renal businesses into a single global business unit. Effective January 1, 2011, the company changed its segment presentation to reflect this new structure, and recast all prior periods presented to conform to the new presentation.

<sup>3</sup> Included net sales related to the U.S. multi-source generic injectables business through the May 2011 divestiture date. The impact on GAAP net sales for total Medical Products and total Baxter was as follows (\$ in millions):

	Q4 2011			Q4 2010			% Growth		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
<b>Total Medical Products</b>	<b>\$726</b>	<b>\$1,287</b>	<b>\$2,013</b>	<b>\$731</b>	<b>\$1,225</b>	<b>\$1,956</b>	<b>(1%)</b>	<b>5%</b>	<b>3%</b>
U.S. multi-source generic injectables business	-	-	-	(55)	-	(55)			
<b>Total Medical Products (Excluding U.S. Multi-Source Generic Injectables Business)</b>	<b>\$726</b>	<b>\$1,287</b>	<b>\$2,013</b>	<b>\$676</b>	<b>\$1,225</b>	<b>\$1,901</b>	<b>7%</b>	<b>5%</b>	<b>6%</b>
<b>Total Baxter</b>	<b>\$1,466</b>	<b>\$2,128</b>	<b>\$3,594</b>	<b>\$1,440</b>	<b>\$2,058</b>	<b>\$3,498</b>	<b>2%</b>	<b>3%</b>	<b>3%</b>
U.S. multi-source generic injectables business	-	-	-	(55)	-	(55)			
<b>Total Baxter (Excluding U.S. Multi-Source Generic Injectables Business)</b>	<b>\$1,466</b>	<b>\$2,128</b>	<b>\$3,594</b>	<b>\$1,385</b>	<b>\$2,058</b>	<b>\$3,443</b>	<b>6%</b>	<b>3%</b>	<b>4%</b>

<sup>4</sup> Represents revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business after the February 2007 divestiture.